Inactive Instrument

Other languages Protalix Biotherapeutics Inc TEL AVIV STOCK EXCHANGE

Equities

US74365A1016

Other languages

Unlock all the news: Be the first to know and act before the market!

Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06
Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023	11/09/23
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23
Protalix Biotherapeutics, Inc. Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases	18/05/23
Chiesi Global Rare Diseases and Protalix Biotherapeutics, Inc. Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease	10/05/23
Protalix Biotherapeutics, Inc. and Chiesi Global Rare Diseases Announces European Commission Grants Marketing Authorization to PRX-102 (Pegunigalsidase Alfa) for the Treatment of Adult Patients with Fabry Disease	05/05/23
Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23
Protalix BioTherapeutics, Inc. Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout	21/03/23
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23
Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. Receives Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease	24/02/23
Insider Buy: Protalix Biotherapeutics	05/01/23
Protalix BioTherapeutics' Joint Resubmission of Application for Fabry Disease Treatment Gets FDA Acceptance	05/12/22
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of A Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease	05/12/22
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease	14/11/22
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22
Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Posts Q2 Revenue $8.8M, vs. Street Est of $2.68M	15/08/22
Protalix BioTherapeutics, Inc. Appoints Shmuel "Muli" Ben Zvi to Its Board of Directors and Audit Committee and Compensation Committee	30/06/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Protalix Biotherapeutics Inc TEL AVIV STOCK EXCHANGE

Equities

US74365A1016

Other languages

Filters